Shattuck’s ARC platform

October 14, 2019

Shattuck’s ARC platform was highlighted in a presentation at ASCO Breakthrough (October 11-13, 2019 in Bangkok, Thailand). An overview of the ARC platform and its unique features in comparison to monoclonal antibodies, as well as the Phase I study of SL-279252 (ClinicalTrials.gov Identifier: NCT03894618) were discussed by Dr. Johanna Bendell, Chief Development Officer of Sarah Cannon Research Institute, during her presentation on Bispecific Antibodies as part of the panel discussion on New Molecular and Immuno-Oncologic Based Therapeutics.